BI 78D3 is a competitive c-Jun N-terminal kinase (JNK) inhibitor with IC50 of 280 nM that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K. target: JNK IC 50: 280 nM 1) BI 78D3 Inhibits JNK interacting protein 1 (JIP1)-JNK binding (IC50= 500 nM) and prevents JNK substrate phosphorylation. 2) I-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes. 3) The reference for animal administration is 25 mg/kg